Characteristics of patients and samples studied
. | . | . | . | . | . | Cytogenetic response status, total nucleated cells . | . | . | |
|---|---|---|---|---|---|---|---|---|---|
| UPN . | Phase at start of imatinib mesylate treatment . | Age, y/sex . | Months from diagnosis to start of imatinib mesylate . | Prior treatment . | Months of imatinib mesylate treatment . | Karyotyping, Ph+/total . | FISH, % BCR/ABL+ cells* . | PCR for BCR/ABL, MNCs . | |
| 144 | AP | 49/M | 7 | IFN/Ara-C | 16 | NE | Neg | NE† | |
| 23 | 0/1 | Neg | NE† | ||||||
| 177 | CP | 52/F | 27 | IFN | 9 | NA | Neg | NA | |
| 14 | 0/20 | Neg | Pos | ||||||
| 17 | 0/20 | Neg | Pos | ||||||
| 22 | 0/20 | Neg | Pos | ||||||
| 26 | 0/20 | Neg | Pos | ||||||
| 191 | AP | 52/F | 11 | IFN | 8 | 0/21 | Neg | NA | |
| 214 | CP | 35/M | 7 | IFN | 12 | 0/20 | Neg | Pos | |
| 222 | CP | 67/F | 57 | IFN | 3 | 0/20 | Neg | Pos | |
| 9 | 0/20 | Neg | Pos | ||||||
| 234 | CP | 45/F | 17 | IFN | 6 | NA | Neg | Pos | |
| 238 | CP | 64/M | 19 | IFN | 6 | 0/20 | Neg | Pos | |
| 12 | 0/20 | Neg | Pos | ||||||
| 248 | CP | 69/M | 2 | — | 11 | 0/20 | Neg | Neg | |
| 255 | CP | 65/M | 23 | IFN | 6 | 0/20 | Neg | Pos | |
| 9 | 0/20 | Neg | Pos | ||||||
| 256 | CP | 39/M | 1 | — | 10 | 0/20 | Neg | Pos | |
| 261 | AP | 47/F | 59 | IFN/Ara-C | 18 | 0/2 | Neg‡ | Pos | |
| 268 | CP | 56/F | 61 | IFN/Ara-C | 4 | 0/20 | Neg | Pos | |
| 276 | CP | 54/F | 51 | IFN | 6 | 0/20 | Neg | Pos | |
| 283 | CP | 61/M | 1 | — | 9 | 0/20 | NA | Pos | |
| 286 | CP | 65/M | 1 | — | 11 | 0/20 | Neg | Pos | |
. | . | . | . | . | . | Cytogenetic response status, total nucleated cells . | . | . | |
|---|---|---|---|---|---|---|---|---|---|
| UPN . | Phase at start of imatinib mesylate treatment . | Age, y/sex . | Months from diagnosis to start of imatinib mesylate . | Prior treatment . | Months of imatinib mesylate treatment . | Karyotyping, Ph+/total . | FISH, % BCR/ABL+ cells* . | PCR for BCR/ABL, MNCs . | |
| 144 | AP | 49/M | 7 | IFN/Ara-C | 16 | NE | Neg | NE† | |
| 23 | 0/1 | Neg | NE† | ||||||
| 177 | CP | 52/F | 27 | IFN | 9 | NA | Neg | NA | |
| 14 | 0/20 | Neg | Pos | ||||||
| 17 | 0/20 | Neg | Pos | ||||||
| 22 | 0/20 | Neg | Pos | ||||||
| 26 | 0/20 | Neg | Pos | ||||||
| 191 | AP | 52/F | 11 | IFN | 8 | 0/21 | Neg | NA | |
| 214 | CP | 35/M | 7 | IFN | 12 | 0/20 | Neg | Pos | |
| 222 | CP | 67/F | 57 | IFN | 3 | 0/20 | Neg | Pos | |
| 9 | 0/20 | Neg | Pos | ||||||
| 234 | CP | 45/F | 17 | IFN | 6 | NA | Neg | Pos | |
| 238 | CP | 64/M | 19 | IFN | 6 | 0/20 | Neg | Pos | |
| 12 | 0/20 | Neg | Pos | ||||||
| 248 | CP | 69/M | 2 | — | 11 | 0/20 | Neg | Neg | |
| 255 | CP | 65/M | 23 | IFN | 6 | 0/20 | Neg | Pos | |
| 9 | 0/20 | Neg | Pos | ||||||
| 256 | CP | 39/M | 1 | — | 10 | 0/20 | Neg | Pos | |
| 261 | AP | 47/F | 59 | IFN/Ara-C | 18 | 0/2 | Neg‡ | Pos | |
| 268 | CP | 56/F | 61 | IFN/Ara-C | 4 | 0/20 | Neg | Pos | |
| 276 | CP | 54/F | 51 | IFN | 6 | 0/20 | Neg | Pos | |
| 283 | CP | 61/M | 1 | — | 9 | 0/20 | NA | Pos | |
| 286 | CP | 65/M | 1 | — | 11 | 0/20 | Neg | Pos | |
Ara-C indicates cytosine arabinoside; NE, not evaluable; neg, negative; NA, not available; pos, positive; —, no prior treatment, excluding hydroxyurea; and UPN, unique patient number.
Upper limit of normal less than or equal to 6% BCR/ABL+ cells.
Variant BCR/ABL breakpoint, not amplified by the primers used.
7% cells had trisomy 8 but were BCR/ABL-.